齐鲁晚报.齐鲁壹点于泊升 施工期间，各项目团队充分抢抓施工黄金期，高效完成桩基施工、土方开挖清运、钢筋安装及混凝土浇 筑工作，顺利完成建设目标任务，下一步将进行钢结构屋盖及建筑屋面安装施工。 项目建成后，将系统完善片区交通、餐饮、住宿等城市功能配套，加速人口与资源集聚，培育"体育 +文旅"融合消费新场景，推动体育产业全链条升级，通过承接国际赛事、品牌展演与投资活动，持续 转化赛事流量为消费增量、提升城市竞争力，以赛事经济撬动城市发展新动能，赋能区域产业升级与城 市能级跃升。 济南起步区黄河体育及科技园区基础设施一期工程游泳馆及全民健身中心施工项目设计为甲级体育建 筑，总建筑面积为16.63万平方米，总座席数约4000座，地上部分为游泳跳水馆和全民健身中心。 济南起步区黄河体育及科技园区基础设施一期工程体育馆建筑面积约10.9万平方米，高41.8米，含1.8万 个观众座席，项目定位篮球、冰球、电子竞技三位一体顶级竞赛中心，集多功能于一体的综合比赛场 地，建筑外立面采用国内首例动态变色三角百叶幕墙，项目建成后可承接国内高水平冰上项目赛事，同 时可满足大型文化活动、中小型会展、日常开放及培训。 近日，由济南城市建设 ...

药捷安康是一家以临床需求为导向、处于注册性临床阶段的生物制药公司,专注于发现及开发肿瘤、炎 症及心脏代谢疾病小分子创新疗法。凭借本身全面融合的内部"ACE"方法,公司已建立六款临床阶段候 选产品及一款临床前阶段候选产品的管线,并计划持续拓展。公司专注于开发具有重大临床价值的同类 首创或同类最佳候选药物,以满足全球未被满足的临床需求。其核心产品Tinengotinib(TT-00420)是一款 处 于 注 册 性 临 床 阶 段 、 自 主 研 发 的 独 特 多 靶 点 激 酶 ("MTK") 抑 制 剂 ( 主 要 靶 向 三 个 关 键 通 路:FGFR/VEGFR、JAK和Aurora激酶)。截至目前,Tinengotinib正在进行两项关键性/注册性临床试验,用 于治疗在过往接受FGFR抑制剂治疗后疾病发生进展的胆管癌("CCA")患者,分别在中国和国际多中心临 床试验("MRCT")进行。 2025年6月23日,创投集团合作子基金南京紫金先进制造产业股权投资中心(有限合伙)(以下简称"紫金先 进制造基金")投资企业——药捷安康(南京)科技股份有限公司(以下简称"药捷安康") 正式于香港联合交 易所有 ...

Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Investor Presentation January 13, 2025 Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking ...

PRESS RELEASE OF PAYCHEX, INC. DATED JUNE 25, 2025 Paychex, Inc. Reports Fourth Quarter and Full Year 2025 Results Rochester, N.Y. (June 25, 2025) - Paychex, Inc. (Nasdaq: PAYX) (the "Company," "Paychex," "we," "our," or "us") today reported results for the fiscal quarter ended May 31, 2025 (the "fourth quarter") and fiscal year ended May 31, 2025 ("fiscal 2025"). Results compared with the same period last year are as follows: | | | | Fourth Quarter | | | | Fiscal Year | | | | --- | --- | --- | --- | --- | ...

Core Insights - Floor & Decor has formed a partnership with Habitat for Humanity International to enhance community stability through safe and affordable housing [1][3] - In 2025, Floor & Decor has donated over $300,000 in flooring and installation materials to more than 60 local Habitat affiliates, impacting over 80 communities across the U.S. [2] - The partnership reflects a shared commitment to improving lives and communities, aligning with the mission of Habitat for Humanity [3][4] Company Overview - Floor & Decor is a leading retailer specializing in hard surface flooring, operating over 250 warehouse-format stores and five design studios across 38 states as of March 27, 2025 [6] - The company offers a wide range of flooring products, including laminate, vinyl, tile, wood, and natural stone, at competitive prices [6] - Founded in 2000 and headquartered in Atlanta, Georgia, Floor & Decor emphasizes continuous improvement in both its business operations and philanthropic efforts [4][6]

深圳商报·读创客户端记者 靳恩琦 新三板挂牌不到4个月的舟山晨光电机股份有限公司（以下简称"晨光电机"）今年1月宣布"转道"北交所，6月25日，该公司发布招股说明书，其IPO申请已获 北交所受理。 ▌实控人夫妻持股逾九成 招股书显示，晨光电机成立于2001年12月19日，于2023年9月4日整体变更设立股份公司，并于2024年9月9日在全国股转系统挂牌并公开转让。 晨光电机从事微特电机的研发、生产和销售，产品主要应用于以吸尘器为主的清洁电器领域。公司能够为客户提供适用于多种应用场景的交流串激电机、直 流无刷电机、直流有刷电机，在清洁电器微特电机细分市场具有较强竞争力。除清洁电器领域外，公司产品也应用于电动工具及其他领域。 但与此同时，晨光电机报告期各期归母净利润分别为0.58亿元、0.99亿元、0.79亿元。受下游行业需求变化、市场竞争、成本变动等综合影响，2024年公司 产品毛利率、销售净利率有所下滑，导致归母净利润较上年度下滑20.84%。 据招股书，公司产品已应用于必胜（Bissell）、鲨客（Shark）、惠而浦（Whirlpool）、百得（Black+Decker）、Candy Hoover、LG、 ...

Fourth Quarter Highlights and Financial Results Fiscal 2025 Copyright 2025, Paychex, Inc. All rights reserved. Confidential and proprietary. 1 Forward Looking Statements Certain written statements in this presentation may contain, and members of management may from time to time make or discuss statements which constitute, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by ...

Core Insights - ReShape Lifesciences has been granted an international patent for its Diabetes Neuromodulation technology, which aims to improve glycemic control in Type 2 diabetes patients [1][2] - The technology utilizes a proprietary vagus nerve block (vBloc™) system combined with bioelectronic modulation to manage glucose levels effectively [2][3] - The patent protection extends until April 12, 2039, enhancing the company's intellectual property position and commercial prospects [1][2] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band® systems and Obalon® balloon technology [4] - The company is focused on innovative approaches to treat obesity and metabolic diseases, with a strong emphasis on personalized medicine [3][4] Technology Details - The Diabetes Neuromodulation system is designed to deliver targeted electrical signals to regulate insulin release and glucose levels, showing promise in preclinical studies [2][3] - The system is considered superior to traditional vagus nerve stimulation methods, as it minimizes side effects and allows for adjustable treatment [3] Market Position - The granting of the Australian patent is seen as a significant milestone that underscores the global relevance of the company's technology and its potential to reduce reliance on daily medications for diabetes management [2] - ReShape Lifesciences holds a robust intellectual property portfolio with 63 issued or pending patents, covering various aspects of its technology [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 Hong Kong Finance Group Limited 香港信貸集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1273） 香港信貸集團有限公司（「公司」或「本公司」）之董事會（「董事會」或「董事」）欣然公佈本公 司及其附屬公司（統稱為「本集團」）截至2025年3月31日止年度之經審核綜合末期業績， 連同去年同期之比較數字如下： 綜合財務狀況表 截 至 2025 年 3 月 31 日止年度之 末期業績公佈 於2025年3月31日 | | | 於3月31日 | | | --- | --- | --- | --- | | | | 2025年 | 2024年 | | | 附註 | 千港元 | 千港元 | | 資產 | | | | | 現金及現金等價物 | | 33,486 | 28,376 | | 應收貸款及利息 | 12 | 781,486 | 894,018 | | 預付款項、按金及其 ...

ACM Research, Inc. March 2025 Investor Presentation 1 DISCLOSURES Forward-looking Statements. Certain statements contained in this presentation are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on ACM Research management's current expectation ...